Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SeroVital is an orally administered dietary supplement developed by Sanmedica International, designed to stimulate the endogenous release of human growth hormone (hGH) from the pituitary gland. It consists of a proprietary blend of amino acids and amino acid derivatives, specifically L-lysine, L-arginine, oxo-proline, N-acetyl-L-cysteine, and L-glutamine, along with the herb Schizonepeta (Japanese catnip). The supplement's primary mechanism of action is the suppression of somatostatin (growth hormone-inhibiting hormone), a natural inhibitor of hGH and thyroid-stimulating hormone (TSH). By inhibiting somatostatin, SeroVital facilitates a significant increase in endogenous hGH levels. Clinical research conducted at the Pennington Biomedical Research Center, including a randomized, double-blind, crossover trial (NCT01540773), demonstrated a 682% increase in mean serum hGH levels 120 minutes after oral administration in healthy volunteers. It is primarily marketed for anti-aging benefits, wellness, and the optimization of growth hormone levels in healthy adults.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SeroVital.